Heron Therapeutics, Inc. (LON:0J4V)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 42.18M -75.2% |
| Revenue (ttm) | 113.94M +1.0% |
| Net Income | -25.66M |
| EPS | -0.14 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,489 |
| Open | 0.2934 |
| Previous Close | 0.2900 |
| Day's Range | 0.2934 - 0.2974 |
| 52-Week Range | 0.2605 - 1.5700 |
| Beta | 1.62 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 6, 2026 |
About Heron Therapeutics
Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company’s product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emeto... [Read more]
Financial Performance
In 2025, Heron Therapeutics's revenue was $154.90 million, an increase of 7.36% compared to the previous year's $144.29 million. Losses were -$20.20 million, 48.7% more than in 2024.
Financial numbers in USD Financial StatementsNews
Heron Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright downgraded Heron Therapeutics (HRTX) to Neutral from Buy without a price target following the Q2 report. Following the adverse Cinvanti patent ruling, withdrawal of the company’s 2026 ...
Heron Therapeutics Earnings Call Transcript: Q2 2026
Q2 2026 net revenue rose to $37.7M, with strong year-over-year growth in acute care products but CINVANTI sales down 10% from last year due to competition. Guidance was withdrawn after a court decision on CINVANTI patents, and spending was tightened as strategic alternatives are considered.
Heron Therapeutics Earnings release: Q2 2026
Heron Therapeutics released its Q2 2026 earnings on August 10, 2026, summarizing the period's financial results.
Heron Therapeutics Quarterly report: Q2 2026
Heron Therapeutics has published its Q2 2026 quarterly earnings report on August 10, 2026.
Heron Therapeutics to Report Second Quarter 2026 Financial Results on Monday, August 10, 2026
CARY, N.C., July 27, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced that the Company will host a...
Heron Therapeutics Transcript: AGM 2026
The meeting saw the election of seven directors, approval of all six proposals including auditor ratification, executive compensation, and amendments to equity and stock purchase plans. No questions were raised by stockholders during the session.
Heron Therapeutics price target lowered to $2 from $4 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Heron Therapeutics (HRTX) to $2 from $4 and keeps a Buy rating on the shares after the company announced that the U.S.
Heron Therapeutics downgraded at Needham after Cinvanti patents invalidated
As previously reported, Needham analyst Serge Belanger downgraded Heron Therapeutics (HRTX) to Hold from Buy with no price target after a judge in the U.S. District Court of Delaware issued…
Heron Therapeutics downgraded to Hold from Buy at Needham
Needham downgraded Heron Therapeutics (HRTX) to Hold from Buy.
U.S. District Court Issues Decision Regarding CINVANTI® Patents
CARY, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced that the U.S. District Court...
Heron Therapeutics price target lowered to $4 from $6 at H.C. Wainwright
H.C. Wainwright analyst Brandon Folkes lowered the firm’s price target on Heron Therapeutics (HRTX) to $4 from $6 and keeps a Buy rating on the shares. The company reported a…
Heron Therapeutics reports Q1 EPS (4c), consensus (2c)
Reports Q1 revenue $34.71M, consensus $36.72M. “Despite typical first-quarter seasonality and unusual weather-related disruption early in the quarter, we saw a clear recovery in February and March,” s...
Heron Therapeutics backs FY26 revenue view $173M-$183M, consensus $174.73M
Backs FY26 adjusted EBITDA view $10M-$20M.
Heron Therapeutics Earnings Call Transcript: Q1 2026
Q1 2026 net sales were $34.7M, impacted by severe weather and seasonal headwinds, but March sales rebounded above $15M. Acute care and oncology portfolios showed strong year-over-year growth, and full-year guidance for $173–$183M in sales and $10–$20M adjusted EBITDA was reaffirmed.
Heron Therapeutics Earnings release: Q1 2026
Heron Therapeutics released its Q1 2026 earnings on May 11, 2026, summarizing the period's financial results.
Heron Therapeutics Quarterly report: Q1 2026
Heron Therapeutics has published its Q1 2026 quarterly earnings report on May 11, 2026.
Heron Therapeutics Slides: Q1 2026
Heron Therapeutics has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 11, 2026.
Heron Therapeutics Announces First Quarter 2026 Financial Results and Reaffirms Guidance
CARY, N.C., May 11, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced financial results for the thr...
Heron Therapeutics Proxy statement: Proxy filing
Heron Therapeutics filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
Heron Therapeutics Proxy statement: Proxy filing
Heron Therapeutics filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
Heron Therapeutics to Report First Quarter 2026 Financial Results on Monday, May 11, 2026
CARY, N.C., April 27, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced that the Company will host ...
Heron Therapeutics Proxy statement: Proxy filing
Heron Therapeutics filed a proxy statement on April 20, 2026, providing details for shareholder voting and corporate governance matters.
Heron Therapeutics Earnings Call Transcript: Q4 2025
Delivered $155M in 2025 net revenues and $14.7M adjusted EBITDA, exceeding guidance. Acute care products ZYNRELEF and APONVIE drove strong growth, while oncology remained stable despite SUSTOL's decline. 2026 guidance targets $173M–$183M sales and $10M–$20M EBITDA.
Heron Therapeutics Annual report: Q4 2025
Heron Therapeutics has published its Q4 2025 annual report on February 26, 2026.
Heron Therapeutics Earnings release: Q4 2025
Heron Therapeutics released its Q4 2025 earnings on February 26, 2026, summarizing the period's financial results.